Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6349876 | 0.96 | DRD2 (0.52) | DRD2LMNASMN1; SMN2HTR1ASIGMAR1 | |
| SCHEMBL11107203 | 0.88 | ADRA2A (0.55) | DRD2LMNASMN1; SMN2HTR1ASIGMAR1 | |
| SCHEMBL6356804 | 0.88 | HTR1A (0.61) | DRD2HTR1ASIGMAR1 | |
| SCHEMBL6350480 | 0.88 | DRD2 (0.48) | DRD2LMNAHTR1ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL11104894 | 0.87 | HTR2C (0.54) | DRD2LMNASMN1; SMN2HTR1ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL11105514 | 0.87 | HTR1A (0.60) | DRD2HTR1ASIGMAR1 | |
| SCHEMBL11107814 | 0.83 | DRD2 (0.56) | DRD2LMNASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL11104487 | 0.81 | ADRA2A (0.56) | DRD2HTR1ASIGMAR1 | |
| SCHEMBL11101519 | 0.80 | NPC1 (0.56) | DRD2SMN1; SMN2HTR1ASIGMAR1 | |
| SCHEMBL11109505 | 0.80 | DRD2 (0.56) | DRD2HTR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1723199-A | 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | DRD2 144/4885LMNA 3152/4885SMN1; SMN2 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.